In 2014, at 28 years old, Stephen Estrada was diagnosed with stage 4 colon cancer and told he had a 1 percent chance of living for the next five years. With this diagnosis came the news that he has a genetic condition known as Lynch Syndrome, an inherited mutation of the mismatch repair DNA pathway that significantly increased his risk for several types of cancer at an early age. He underwent surgery, chemotherapy, and a NanoKnife procedure, which ultimately failed. At this point, Stephen worked with his oncologist to research other treatment options for colorectal cancer patients with Lynch Syndrome. He enrolled in a phase 1 clinical trial combining chemotherapy with the immunotherapy atezolizumab (TECENTRIQ®). Since beginning immunotherapy over seven years ago, his disease has remained stable. Stephen has married, bought a home, and become an advocate for fellow cancer patients as well as a CRI ImmunoAdvocate.